Research Grants
May 2002 . November 2002 . May 2003 . November 2003 . May 2004 . May 2005 . November 2005 . May 2006 . November 2006 . May 2007 . November 2007 . November 2008
7th Grant Competition - November, 2005
Eleven projects aimed at development of promising new cancer treatments received approximately $5.3 million from the Cancer Research Fund. By funding 81 cancer research projects from 7 competitions the OCRN is providing over $44 million across 16 Ontario sites.
| Principal Investigator | Institution | Project Type/Title | Award* |
| Diamandis, Eleftherios | Mount Sinai Hospital | Translational: Human kallikrein 8 - a novel biomarker for ovarian carcinoma | $468,000 |
| Filmus, Jorge | Sunnybrook and Women's College Health Sciences Centre | Translational: Soluble glypican-3 as a therapeutic tool against hepatocellular carcinoma | $297,600 |
| Hedley, David | University Health Network | Translational: Real time pharmacodynamic monitoring of molecular-targeted agents in leukemia patients | $517,680 |
| Holloway, Claire | Sunnybrook and Women's College Health Sciences Centre | Clinical: A phase I/II Trial of 111In-DTPA-trastuzumab fab injection for radioimmunoguided surgery in women with HER2/neu-positive breast cancer | $312,068 |
| Kamel Reid, Suzanne | University Health Network | Translational: Genomic and proteomic analysis of downstream targets in APL: mechanisms of response and resistance to therapy | $566,010 |
| Lorimer, Ian | Ottawa Health Research Institute | Companion: Molecular predictors of outcome in BR.19, a phase III trial of adjuvant gefitinib in post-resection, early stage non-small cell lung cancer | $476,640 |
| Mak, Tak | University Health Network | Translational: Cancer therapy targets in the PTEN/P1-3'K signaling network | $703,704 |
| Medin, Jeffrey | University Health Network | Translational: Immunogene therapy for prostate cancer - testing outcomes in non-human primates | $672,120 |
| Mossman, Karen | McMaster University | Translational: Herpes virus-based oncolytic viruses for cancer therapy | $424,080 |
| Penn, Linda | University Health Network | Translational: Statin-induced apoptosis | $415,580 |
| Prud'homme, Gerald | St. Michael's Hospital | Translational: Drug-mediated inhibition of TGF-beta for cancer immunotherapy | $464,933 |
* Includes a value of 20 per cent added for institution overhead.